Bortezomib and Dry eyes aggravated - a phase IV clinical study of FDA data

Summary:

Dry eyes aggravated is reported as a side effect among people who take Bortezomib (bortezomib), especially for people who are female, 50-59 old, also take Gabapentin, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Dry eyes aggravated when taking Bortezomib. It is created by eHealthMe based on reports of 30,902 people who have side effects when taking Bortezomib from the FDA, and is updated regularly.

What is Bortezomib?

Bortezomib has active ingredients of bortezomib. eHealthMe is studying from 30,912 Bortezomib users. Check the latest studies of Bortezomib.

What is Dry eyes aggravated?

Dry eyes aggravated is found to be associated with 1,232 drugs and 502 conditions by eHealthMe. Check the latest studies of Dry eyes aggravated.

On Jul, 19, 2026

30,902 people reported to have side effects when taking Bortezomib.
Among them, 39 people (0.13%) have Dry eyes aggravated.

Could Bortezomib cause Dry eyes aggravated?

Among these 39 people:

What is the gender of people who have Dry eyes aggravated when taking Bortezomib? *

female: 57.14 %
male: 42.86 %

What is the age of people who have Dry eyes aggravated when taking Bortezomib? *

What are other drugs people take besides Bortezomib? *

What are other side effects people have besides Dry eyes aggravated? *

Neuropathy Peripheral (surface nerve damage): 26 people, 66.67%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 20 people, 51.28%
Infection: 18 people, 46.15%
Depression: 18 people, 46.15%
Joint Pain: 18 people, 46.15%
Stress And Anxiety: 18 people, 46.15%
Osteonecrosis Of Jaw (death of bone of jaw): 18 people, 46.15%
Neck Pain: 17 people, 43.59%
Diarrhea: 17 people, 43.59%
Deformity (disfigurement): 17 people, 43.59%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 22 people, 56.41%
Acute Graft Versus Host Disease In Skin (acute complication on skin following an allogeneic tissue/blood transplant): 5 people, 12.82%
Pain: 4 people, 10.26%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 4 people, 10.26%
Nausea (feeling of having an urge to vomit): 4 people, 10.26%
Diarrhea: 3 people, 7.69%
Irritability: 3 people, 7.69%
Erection Problems: 3 people, 7.69%
Platelet Count Abnormal: 2 people, 5.13%
Chronic Graft Versus Host Disease In Skin (damage by immune cells to skin after grafting): 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Bortezomib and have Dry eyes aggravated?

- Check whether Dry eyes aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Bortezomib:

Bortezomib (30,912 reports)

Browse all side effects of Bortezomib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dry eyes aggravated:

Dry eyes aggravated (1,232 drugs)

Browse all the conditions that are associated with Dry eyes aggravated:

Dry eyes aggravated (502 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bortezomib (the active ingredients of Bortezomib) and Bortezomib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.